This Policy Statement was retired June 2012. The purpose of this statement is to provide the
rationale and recommendations for adolescent use of tetanus toxoid, reduced diphtheria …

During spring 2005, two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccine (Tdap) products formulated for use in adolescents (and, for one product, use in …

Bordetella pertussis is a highly contagious bacterium known to cause pertussis (whooping
cough) and is transmitted via airborne droplets. Although childhood vaccination has …

This Policy Statement was retired January 2015. The American Academy of Pediatrics and
the Centers for Disease Control and Prevention are amending previous recommendations …

Acellular pertussis vaccines combined with diphtheria and tetanus toxoids have proven to
be well tolerated, immunogenic and effective in reducing pertussis disease in adolescents …

Pertussis is the only disease for which children are routinely vaccinated that is not at
historically low levels in the United States. The increases seen in pertussis are not due to …

Summary On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine (Tdap) formulated for use in adults and adolescents was licensed in the …

BACKGROUND: For the first time, pertussis vaccines for adolescents and adults (combined
with tetanus and diphtheria toxoids [Tdap]) became available in the United States in 2005 …

Pertussis is the only vaccine-preventable disease on the rise in the United States, with
increasing incidence in adolescents and adults related to waning immunity. Although often …

Objectives To describe the epidemiology of infant pertussis in King County, Washington, and
to better understand the implications for tetanus toxoid, reduced diphtheria toxoid, and …